From Lipid Screening to Commercialization

Curia develops and manufactures custom ionizable lipids, PEG lipids and phospholipids used in lipid nanoparticles (LNPs). Its offering connects chemical synthesis with purification, analytical methods and manufacturing scale-up. The fact sheet explains how understanding the source of impurities can inform synthesis changes and purification decisions as a lipid moves toward commercial production.

Download Fact Sheet

How Curia supports lipid scale-up

• Development linked to manufacturing. Services span gram-scale work and multi-kilogram scale-up under non-GMP and GMP conditions, with manufacturing lines offering capacity into the ton range. The appropriate production scale depends on the lipid and process.
• Purification informs route development. Curia evaluates where impurities arise in synthesis and uses that knowledge to optimize the process. Chromatography capabilities include normal-phase, reverse-phase and ion-exchange systems, with columns up to 500 L and automated fraction collection, analysis and pooling.
• Analytical and supply requirements are part of the plan. The offering includes method development and validation, reference standards, charged aerosol detection (CAD) for non-chromophoric lipids, cold storage, flexible packaging and regulatory support.

Read From Lipid Screening to Commercialization for the full capability list, impurity-management approach and global network. The fact sheet can help your team define its lipid synthesis, purification and supply requirements.

Explore industrial chromatography
Explore LNP formulation services